SpringWorks Therapeutics

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company's product candidate, nirogacestat, is an oral, small molecule gamma secretase inhibitor for the treatment of desmoid tumors, a rare and often debilitating and disfiguring soft tissue tumor. The company's second product candidate is mirdametinib, an oral, small molecule MEK inhibitor for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, a rare tumor of the peripheral nerve sheath that causes pain and disfigurement.
  • TickerSWTX
  • ISINUS85205L1070
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
David Nierengarten
  • David Nierengarten
 PRESS RELEASE
SWTX SpringWorks The... (Health Care)

SpringWorks Therapeutics Announces Presentation of Updated Interim Dat...

SpringWorks Therapeutics Announces Presentation of Updated Interim Data from the Phase 2b ReNeu Trial at the 2021 Children’s Tumor Foundation NF Conference Additional Follow-up of First 20 Adult Patients Enrolled Continues to Show Encouraging Efficacy and Tolerability of Mirdametinib in Patients with NF1-PN STAMFORD, Conn., June 15, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that an update on the previous...

David Nierengarten
  • David Nierengarten
 PRESS RELEASE
SWTX SpringWorks The... (Health Care)

SpringWorks Therapeutics Announces Clinical Collaboration with Seagen ...

SpringWorks Therapeutics Announces Clinical Collaboration with Seagen to Evaluate Nirogacestat in Combination with SEA-BCMA in Patients with Relapsed or Refractory Multiple Myeloma Continued Execution on Strategy to Advance Nirogacestat as a BCMA Potentiator Across Modalities STAMFORD, Conn., June 07, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that the company has entered into a clinical trial collaborati...

 PRESS RELEASE
SWTX SpringWorks The... (Health Care)

SpringWorks Therapeutics to Present at the Goldman Sachs 42nd Annual G...

SpringWorks Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference STAMFORD, Conn., June 01, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a Fireside Chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8th at 3:00PM ET. To access the live webcast please visit the Events & Presentations page within the Investors ...

 PRESS RELEASE
SWTX SpringWorks The... (Health Care)

SpringWorks Therapeutics Announces Presentation of Updated Interim Dat...

SpringWorks Therapeutics Announces Presentation of Updated Interim Data from the Phase 2b ReNeu Trial at the 2021 Children’s Tumor Foundation NF Conference Additional Follow-up of First 20 Adult Patients Enrolled Continues to Show Encouraging Efficacy and Tolerability of Mirdametinib in Patients with NF1-PN STAMFORD, Conn., June 15, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that an update on the previous...

 PRESS RELEASE
SWTX SpringWorks The... (Health Care)

SpringWorks Therapeutics Announces Clinical Collaboration with Seagen ...

SpringWorks Therapeutics Announces Clinical Collaboration with Seagen to Evaluate Nirogacestat in Combination with SEA-BCMA in Patients with Relapsed or Refractory Multiple Myeloma Continued Execution on Strategy to Advance Nirogacestat as a BCMA Potentiator Across Modalities STAMFORD, Conn., June 07, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that the company has entered into a clinical trial collaborati...

 PRESS RELEASE
SWTX SpringWorks The... (Health Care)

SpringWorks Therapeutics to Present at the Goldman Sachs 42nd Annual G...

SpringWorks Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference STAMFORD, Conn., June 01, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a Fireside Chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8th at 3:00PM ET. To access the live webcast please visit the Events & Presentations page within the Investors ...

 PRESS RELEASE
SWTX SpringWorks The... (Health Care)

SpringWorks Therapeutics Reports First Quarter 2021 Financial Results ...

SpringWorks Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Highlights – Reported Interim Data from Phase 2b ReNeu Trial of Mirdametinib in NF1-PN Demonstrating Encouraging Clinical Activity and Tolerability in the First 20 Adult Patients Enrolled – – Announced Achievement of First Patient Dosed in Allogene and Janssen Phase 1 Trials Evaluating Nirogacestat in Combination with BCMA Therapies – – Expanded Targeted Oncology Pipeline with Exclusive Worldwide License to TEAD Inhibitor Portfolio – STAMFORD, Conn., May 06, 2021 (GLOBE NEWSWIRE) -- SpringWorks Th...

 PRESS RELEASE
SWTX SpringWorks The... (Health Care)

SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2020 Fin...

SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights - Reported Interim Data from Phase 2b ReNeu Trial of Mirdametinib in NF1-PN Demonstrating Encouraging Clinical Activity and Tolerability in the First 20 Adult Patients Enrolled -- Allogene- and Janssen-Sponsored Phase 1 Trials Evaluating Nirogacestat in Combination with BCMA Therapies Have Initiated - - Continued to Strengthen Nirogacestat Patent Portfolio - - Multiple Data Readouts Expected in 2021 Across Pipeline, Including Topline Data from Phase 3 DeFi Trial in Desmoid T...

David Nierengarten
  • David Nierengarten
David Nierengarten
  • David Nierengarten
David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus

ResearchPool Subscriptions

Get the most out of your insights

Get in touch